文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

临时经静脉膈神经刺激辅助撤机(RESCUE-3):一项随机临床试验

Temporary Transvenous Diaphragm Neurostimulation for Weaning from Mechanical Ventilation (RESCUE-3): A Randomized Clinical Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2026-01-01
一句话结论对机械通气≥96小时、符合撤机条件但至少两次撤机失败的患者,每日两次经静脉膈神经刺激可能提高30天撤机成功率,但严重不良事件可能增加。

RESCUE-3为国际多中心、开放标签随机临床试验,纳入机械通气≥96小时、符合撤机条件且至少两次撤机失败的成人患者,随机接受每日两次经静脉膈神经刺激(治疗组)或标准治疗(对照组)。因入组缓慢和经费考虑,试验在200例患者随机后第一次期中分析时提前终止;改良意向性治疗人群共216例(治疗组102例,对照组114例)。第30天治疗组71例(70%)成功撤机,对照组69例(61%),校正风险比1.34(95%可信区间1.01-1.78),后验优越概率97.9%;治疗组通气时间缩短(校正差值-2.5天,95%可信区间-5.0至0.1),后验优越概率97.1%。治疗组严重不良事件发生率36%,对照组24%;治疗组9.8%死亡,对照组10.5%死亡(校正风险比0.74,95%可信区间0.37-1.46)。

要点

  • 纳入标准:成人机械通气≥96小时、符合撤机条件且至少两次撤机失败。
  • 第30天成功撤机:治疗组70%(71/102) vs 对照组61%(69/114),校正风险比1.34(95%可信区间1.01-1.78),后验优越概率97.9%。
  • 通气时间:治疗组较对照组缩短2.5天(校正差值-2.5天,95%可信区间-5.0至0.1),后验优越概率97.1%。
  • 严重不良事件:治疗组36% vs 对照组24%;死亡:治疗组9.8% vs 对照组10.5%(校正风险比0.74,95%可信区间0.37-1.46)。
  • 试验因入组缓慢和经费考虑在第一次期中分析后提前终止。

适用人群与场景

  • 成人患者,机械通气≥96小时,符合撤机条件,且至少两次撤机失败。

诊断标准与关键阈值

  • 纳入标准:机械通气≥96小时且符合撤机条件、至少两次撤机失败。
  • 主要结局:第30天成功撤机。

处置流程与药物剂量

  • 治疗组:每日两次经静脉膈神经刺激;对照组:标准治疗。

研究设计与关键结果

  • 国际多中心、开放标签随机临床试验(RESCUE-3),因入组缓慢和经费考虑在200例患者随机后第一次期中分析时提前终止。
  • 改良意向性治疗人群216例:治疗组102例,对照组114例。
  • 第30天成功撤机:治疗组71例(70%) vs 对照组69例(61%),校正风险比1.34(95%可信区间1.01-1.78),后验优越概率97.9%。
  • 通气时间:治疗组较对照组缩短2.5天(校正差值-2.5天,95%可信区间-5.0至0.1),后验优越概率97.1%。
  • 严重不良事件:治疗组36% vs 对照组24%。
  • 死亡:治疗组9.8% vs 对照组10.5%,校正风险比0.74(95%可信区间0.37-1.46),后验优越概率80.6%。

证据类型、等级与局限

  • 证据类型:国际多中心、开放标签随机临床试验。
  • 预设主要分析采用贝叶斯方法,借用先前II期随机试验的先验信息并降权处理试验间可能差异。
  • 局限:因入组缓慢和经费考虑,试验在第一次期中分析后提前终止。

对床旁实践的改变

  • 对机械通气≥96小时、符合撤机条件且至少两次撤机失败的成人患者,每日两次经静脉膈神经刺激可能提高第30天成功撤机率(治疗组70% vs 对照组61%),但严重不良事件可能增加(36% vs 24%)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

RATIONALE: Diaphragm dysfunction impedes weaning from mechanical ventilation. Transvenous diaphragm neurostimulation can increase diaphragm strength, but its impact on patient outcomes is uncertain.

OBJECTIVES: To test the safety and effectiveness of transvenous diaphragm neurostimulation to increase successful weaning in patients with difficulty weaning from mechanical ventilation in comparison with standard of care.

METHODS: This international, multicenter, open-label, randomized clinical trial (RESCUE-3) included adult patients requiring mechanical ventilation for ⩾96 hours who met readiness-to-wean criteria and failed two or more weaning attempts. Patients were randomized to twice-daily transvenous diaphragm neurostimulation (treatment) or standard of care (control). The primary outcome was successful weaning at Day 30. Secondary outcomes included duration of ventilation to Day 30 and mortality at Day 30. The prespecified primary analysis utilized a Bayesian approach with borrowing of prior information from a previous Phase-II randomized trial, downweighted to account for possible differences in trials.

MEASUREMENTS AND MAIN RESULTS: Because of slow enrollment and financial considerations, the trial was halted at the first interim analysis after 200 patients were randomized. Overall, 216 patients were randomized in the modified intent-to-treat population (treatment group, n = 102; control group n = 114). At Day 30, 71 (70%) patients in the treatment group and 69 (61%) patients in the control group were successfully weaned (adjusted hazard ratio, 1.34; 95% credible interval = 1.01-1.78; posterior probability of superiority, 97.9%). Treatment reduced the duration of ventilation (adjusted difference, -2.5 d; 95% credible interval = -5.0 to 0.1; posterior probability of superiority, 97.1%). Serious adverse events were reported in 36% of patients in the treatment group and 24% of patients in the control group; 9.8% of patients in the treatment group and 10.5% of patients in the control group died (adjusted hazard ratio, 0.74; 95% credible interval = 0.37-1.46; posterior probability of superiority, 80.6%).

CONCLUSIONS: Although the trial was stopped early because of slow enrollment, transvenous diaphragm neurostimulation showed a high probability of potential benefit for weaning success but with a possible increase in serious adverse events.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Dres M, Ewert R, Conrad SA, et al. Temporary Transvenous Diaphragm Neurostimulation for Weaning from Mechanical Ventilation (RESCUE-3): A Randomized Clinical Trial. Am J Respir Crit Care Med. 2026. PMID: 40498082. doi:10.1164/rccm.202505-1056OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。